Role of traditional Chinese Medicine in prevention and treatment of chronic hepatitis B liver fibrosis: Current status, challenges, and thoughts
10.3969/j.issn.1001-5256.2023.06.004
- VernacularTitle:中医药防治慢性乙型肝炎肝纤维化的现状、挑战与思考
- Author:
Meijie SHI
1
;
Huanming XIAO
1
;
Yubao XIE
1
;
Sheng LI
1
;
Folai ZENG
1
;
Xiaoling CHI
1
Author Information
1. Department of Hepatology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China
- Publication Type:Discussions by Experts
- Keywords:
Hepatitis B, Chronic;
Hepatic Fibrosis;
Anti-Hepato Fibrosis Agents (TCM)
- From:
Journal of Clinical Hepatology
2023;39(6):1280-1286
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, significant breakthroughs have been made in the research on the role of traditional Chinese medicine (TCM) in the prevention and treatment of chronic hepatitis B liver fibrosis. In terms of clinical research, several multicenter randomized double-blind controlled studies have been conducted with liver pathological changes as the main efficacy evaluation indicator, which have improved the level of evidence in clinical research on the TCM prevention and treatment of liver fibrosis. As for basic research, in-depth studies have been conducted on the mechanism of action of TCM in intervening against liver fibrosis at various levels, including the effect on HSC activation, apoptosis and autophagy, inhibition of liver inflammatory injury, immunoregulation, and inhibition of hepatic sinusoidal capillarization, thereby highlighting the advantages and research difficulties of TCM through "multiple components, targets, and pathways". Under the guidance of Implementation Plan for the Major Projects of Revitalizing and Developing TCM, it is crucial to conduct high-quality clinical and basic research on TCM in the treatment of liver fibrosis, produce high-quality industry achievements, and thus help TCM to be recognized around the world.
